Compare J B Hunt Transport Services Inc (JBHT) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Novo Nordisk A/S — how do they compare? J B Hunt Transport Services Inc trades at $272.78 (market cap $24.92B), while Novo Nordisk A/S trades at $46.18 (market cap $207.85B). The key difference: Novo Nordisk A/S is far larger — about 8.3× J B Hunt Transport Services Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| JBHT | NVO | |
|---|---|---|
Market Cap | $24.92B | $207.85B |
Sector | Industrials | Health |
52-Week High | $298.41 | $63.98 |
52-Week Low | $130.65 | $35.29 |
Enterprise Value | $26.06B | $222.55B |
Dividend Yield | 0.68% | 3.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT stock trades at $266.14, down 0.89% on the day, with a bearish technical signal but strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue trends show stabilization after a decline from 2022 peaks, while profitability metrics like ROE at 18.45% and net margin at 5.31% reflect efficient operations. Recent news highlights the company's 65th anniversary and partnerships to enhance freight technology.
The outlook is positive with a consensus price target of $299.82, implying 12.6% upside, supported by analyst buy ratings (57.78%). Risks include economic sensitivity impacting freight demand and competitive pressures. Earnings execution and intermodal demand recovery are key catalysts for stock appreciation.
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
